Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 1;2(1):81-86.
doi: 10.1089/can.2017.0009. eCollection 2017.

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans

Free PMC article

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans

Gerhard Nahler et al. Cannabis Cannabinoid Res. .
Free PMC article


Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9-tetrahydrocannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to in vivo conditions. Unsurprisingly, the conversion of oral CBD to THC and its metabolites has not been observed to occur in vivo, even after high doses of oral CBD. In addition, the typical spectrum of side effects of THC, or of the very similar synthetic cannabinoid nabilone, as listed in the official Summary of Product Characteristics (e.g., dizziness, euphoria/high, thinking abnormal/concentration difficulties, nausea, tachycardia) has not been observed after treatment with CBD in double-blind, randomized, controlled clinical trials. In conclusion, the conversion of CBD to THC in SGF seems to be an in vitro artifact.

Keywords: acid-catalyzed cyclization; cannabidiol; degradation; delta9-tetrahydrocannabinol; gastric fluid; isomerization.

Conflict of interest statement

G.N. is manager of an independent consultancy firm and medical advisor of Trigal Pharma GmbH. F.G. is Executive Director of IACM,, and medical advisor of MedCann, A.W.Z. and J.A.C. are coinventors (Mechoulam R, JC, Guimaraes FS, AZ, JH, Breuer A) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023”; Def. US No. Reg. 62193296; 29/07/2015; INPI em 19/08/2015 (BR1120150164927). University of São Paulo licensed it to Phytecs Pharm (Resolução USP No. 15.1.130002.1.1). University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil): “Desenvolvimento de um produto farmacêutico contendo canabidiol sintético e comprovação de sua segurança e eficácia terapêutica na epilepsia, esquizofrenia, doença de Parkinson e transtornos de ansiedade.” J.A.C. received a travel support from BSPG-Pharm.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles


    1. Merrick J, Lane B, Sebree T, et al. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1:102–112 - PMC - PubMed
    1. Bonn-Miller MO, Banks SL, Sebree T. Conversion of cannabidiol following oral administration: authors' response to Grotenhermen et al. Cannabis Cannabinoid Res. 2017;2:5–7 - PMC - PubMed
    1. Grotenhermen F, Russo E, Zuardi AW. Even high doses of oral cannabidol do not cause THC-like effects in humans: Comment on Merrick et al. 2016. Cannabis Cannabinoid Res. 2017;2:1–4 - PMC - PubMed
    1. Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br J Pharmacol. 2015;172:4790–4805 - PMC - PubMed
    1. Watanabe K, Itokawa Y, Yamaori S, et al. Conversion of cannabidiol to D9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicol. 2007;25:16–21

LinkOut - more resources